Accessgraph

The CMS ACCESS model and its tools directory create a focused procurement surface, while the supplied research confirms accepted organizations, rolling admissions through 2033, an open interface test suite, and no reviewed commercial comparison layer. A large healthcare research incumbent charges enterprise membership prices, suggesting room for a narrower product.

Accessgraph should not rank tools from marketing copy or call one interface test compatible. It separates official directory facts, vendor-submitted claims, independently reproduced tests, health-system requirements, security and privacy evidence, implementation references, commercial terms, outcome-measure mappings, reviewer findings, and final procurement decisions. Tests bind exact versions, configurations, profiles, data and environments; a PASS does not prove production interoperability, safety, security, clinical value, or CMS approval.

The comparator should use synthetic or vendor test data and avoid patient records. Vendors can respond to findings and correct claims. Sponsorship, membership, referral fees, and commercial relationships remain disclosed and cannot alter results or rank. CMS, health systems, clinicians, procurement, security, privacy, and patients retain their own authority.

Health-system innovation, procurement, interoperability, clinical operations, and technology leaders participating in or evaluating the CMS ACCESS model.